Immunitybio Operating Profit Margin from 2010 to 2025

IBRX Stock  USD 3.29  0.43  15.03%   
Immunitybio Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin will likely drop to -550.36 in 2025. During the period from 2010 to 2025, Immunitybio Operating Profit Margin regression line of annual values had r-squared of  0.04 and arithmetic mean of (754.56). View All Fundamentals
 
Operating Profit Margin  
First Reported
2010-12-31
Previous Quarter
(524.16)
Current Value
(550.36)
Quarterly Volatility
912.0676073
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.8 M, Interest Expense of 156 M or Selling General Administrative of 91.7 M, as well as many indicators such as Price To Sales Ratio of 6.7 K, Dividend Yield of 0.0 or Days Sales Outstanding of 1.6 K. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
  
Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Operating Profit Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Immunitybio over the last few years. It is Immunitybio's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.
Operating Profit Margin10 Years Trend
Pretty Stable
   Operating Profit Margin   
       Timeline  

Immunitybio Operating Profit Margin Regression Statistics

Arithmetic Mean(754.56)
Geometric Mean148.99
Coefficient Of Variation(120.87)
Mean Deviation728.59
Median(365.09)
Standard Deviation912.07
Sample Variance831,867
Range2.8K
R-Value(0.19)
Mean Square Error857,788
R-Squared0.04
Significance0.47
Slope(37.14)
Total Sum of Squares12.5M

Immunitybio Operating Profit Margin History

2025 -550.36
2024 -524.16
2023 -582.4
2022 -1463.74
2021 -353.62
2020 -365.09
2019 -70.96

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's Operating Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Profit Margin(524.16)(550.36)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.